Related Experiment Video
Updated: Jul 2, 2025
Stereotactic Radiosurgery for Gynecologic Cancer
Published on: April 17, 2012
Recent Therapeutic Advances in Gynecologic Oncology: A Review
Elise M Wilson1, Ramez N Eskander1, Pratibha S Binder1
1Moores Cancer Center, Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California San Diego, San Diego, CA 92037, USA.
Abstract:
Gynecologic malignancies have high incidence rates both nationally and internationally, and cervical, endometrial, and ovarian cancers account for high mortality rates worldwide. Significant research is ongoing to develop targeted therapies to address unmet needs in the field and improve patient outcomes. As tumors mutate and progress through traditional lines of treatment, new therapies must be developed to overcome resistance and target cancer-specific receptors and mutations. Recent advances in the development of immunotherapy and antibody-drug conjugates have resulted in compelling and clinically meaningful results in cervical, endometrial, and ovarian cancers. In the last decade, several immunotherapy agents have received FDA approval or NCCN guideline recommendation for the treatment of gynecologic malignancies, including dostarlimab for advanced or recurrent endometrial cancer and pembrolizumab for advanced or recurrent cervical and endometrial cancers. Several other immunotherapeutic agents are under active investigation. Development of antibody-drug conjugates including tisotumab vedotin in cervical cancer, mirvetuximab soravtansine in ovarian cancer, and trastuzumab deruxtecan in multiple gynecologic cancers has translated into exciting efficacy signals, prompting full drug approvals and additional investigation. This article aims to review recent novel advances in targeted treatments for gynecologic malignancies, highlighting the trials and data underlying these novel interventions.
Insights
Novel immunotherapies and antibody-drug conjugates show promise for treating gynecologic cancers like cervical, endometrial, and ovarian cancers, offering new hope against treatment resistance and improving patient outcomes.
Area of Science:
- Oncology
- Immunotherapy
- Drug Development
Background:
- Gynecologic malignancies, including cervical, endometrial, and ovarian cancers, present significant global health challenges with high incidence and mortality rates.
- Traditional treatments face limitations due to tumor mutation and treatment resistance, necessitating the development of novel therapeutic strategies.
- Targeted therapies are crucial for addressing unmet needs and improving outcomes in gynecologic cancer patients.
Purpose of the Study:
- To review recent advancements in targeted treatments for gynecologic malignancies.
- To highlight the clinical trials and data supporting novel immunotherapies and antibody-drug conjugates.
- To discuss the potential of these new interventions in overcoming treatment resistance.
Main Methods:
- Review of recent clinical trials and FDA-approved therapies for gynecologic cancers.
- Analysis of data from immunotherapy agents like dostarlimab and pembrolizumab.
- Examination of antibody-drug conjugates such as tisotumab vedotin, mirvetuximab soravtansine, and trastuzumab deruxtecan.
Main Results:
- Immunotherapy agents have gained FDA approval and NCCN guideline recommendations for advanced or recurrent gynecologic cancers.
- Antibody-drug conjugates have demonstrated significant efficacy signals, leading to drug approvals and further research.
- Novel targeted treatments are showing compelling and clinically meaningful results in cervical, endometrial, and ovarian cancers.
Conclusions:
- Recent advances in immunotherapy and antibody-drug conjugates offer promising new treatment options for gynecologic malignancies.
- These novel agents are crucial for overcoming resistance to traditional therapies and improving patient survival.
- Ongoing research and clinical investigations continue to expand the therapeutic landscape for gynecologic cancers.
More Related Videos
Related Concept Videos
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...